Oragenics To Acquire Odyssey Health's Assets Related To Its Proprietary Neurological Drug Therapies And Technologies; Asset Purchase Includes Cash Payments Of $1.0M And 8M Shares Of Preferred Stock
Portfolio Pulse from Benzinga Newsdesk
Oragenics is set to acquire Odyssey Health's assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as Odyssey's proprietary powder formulation and nasal delivery device. The deal, expected to close in Q4 2023, includes cash payments of $1.0M and 8M shares of Oragenics' Series F Convertible Preferred Stock.
October 05, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Odyssey Health is selling its neurological drug therapies and technologies to Oragenics, which could impact its future revenue streams.
The sale of its neurological drug therapies and technologies could potentially impact Odyssey Health's future revenue streams, which could negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Oragenics is acquiring Odyssey Health's neurological drug therapies and technologies, which could potentially expand its product portfolio and market reach.
The acquisition of Odyssey Health's assets could potentially expand Oragenics' product portfolio and market reach, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100